Erik Mogalian

1.3k total citations
29 papers, 525 citations indexed

About

Erik Mogalian is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Erik Mogalian has authored 29 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 10 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in Erik Mogalian's work include Hepatitis C virus research (14 papers), HIV/AIDS drug development and treatment (8 papers) and Inhalation and Respiratory Drug Delivery (5 papers). Erik Mogalian is often cited by papers focused on Hepatitis C virus research (14 papers), HIV/AIDS drug development and treatment (8 papers) and Inhalation and Respiratory Drug Delivery (5 papers). Erik Mogalian collaborates with scholars based in United States, Australia and New Zealand. Erik Mogalian's co-authors include Anita Mathias, Diana M. Brainard, Polina German, Paul B. Myrdal, John McNally, Kimberly L. Garrison, John G. McHutchison, Brian Doehle, Anu Osinusi and Lingling Han and has published in prestigious journals such as Annals of Internal Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Erik Mogalian

28 papers receiving 498 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Mogalian United States	13	350	313	154	43	33	29	525
Trana Hussaini Canada	12	243 0.7×	296 0.9×	155 1.0×	18 0.4×	44 1.3×	47	518
J.M. Moreno Planas Spain	16	426 1.2×	344 1.1×	33 0.2×	16 0.4×	25 0.8×	44	728
Edmund Tse Australia	11	319 0.9×	335 1.1×	217 1.4×	14 0.3×	35 1.1×	37	623
E Zehnter Germany	10	246 0.7×	247 0.8×	44 0.3×	55 1.3×	29 0.9×	36	457
Luis Viola Argentina	12	268 0.8×	293 0.9×	33 0.2×	67 1.6×	21 0.6×	32	493
Terry Box United States	10	269 0.8×	218 0.7×	48 0.3×	92 2.1×	25 0.8×	32	492
Christophe Bazin France	14	256 0.7×	172 0.5×	61 0.4×	77 1.8×	26 0.8×	35	593
Marie‐Claude Gagnieu France	19	239 0.7×	273 0.9×	278 1.8×	63 1.5×	169 5.1×	63	889
Nickolas Kontorinis United States	11	353 1.0×	316 1.0×	108 0.7×	8 0.2×	8 0.2×	21	513
Rehab Badawi Egypt	13	222 0.6×	230 0.7×	82 0.5×	23 0.5×	55 1.7×	45	442

Countries citing papers authored by Erik Mogalian

Since Specialization

Citations

This map shows the geographic impact of Erik Mogalian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Mogalian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Mogalian more than expected).

Fields of papers citing papers by Erik Mogalian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Mogalian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Mogalian. The network helps show where Erik Mogalian may publish in the future.

Co-authorship network of co-authors of Erik Mogalian

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Mogalian. A scholar is included among the top collaborators of Erik Mogalian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Mogalian. Erik Mogalian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sager, Jennifer E., Sergio Parra, Jennifer Moore, et al.. (2024). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 117(3). 759–767.

Sager, Jennifer E., Alessia Peter, Michael Schmid, et al.. (2024). A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrobial Agents and Chemotherapy. 68(4). e0127323–e0127323. 4 indexed citations

Sager, Jennifer E., Julie Passarell, Xiaobin Li, et al.. (2023). Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19. CPT Pharmacometrics & Systems Pharmacology. 12(6). 853–864. 5 indexed citations

Gupta, Sneha, Valerie A. Clausen, Jing Li, et al.. (2021). Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs in R&D. 21(4). 455–465. 19 indexed citations

Garrison, Kimberly L., Polina German, Erik Mogalian, & Anita Mathias. (2018). The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection. Drug Metabolism and Disposition. 46(8). 1212–1225. 51 indexed citations

Mogalian, Erik, Diana M. Brainard, Anu Osinusi, et al.. (2018). Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Clinical Pharmacokinetics. 57(11). 1449–1457. 9 indexed citations

Lawitz, Eric, Charles Landis, Benedict Maliakkal, et al.. (2017). Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment.. 66. 13 indexed citations

Wyles, David, Norbert Bräu, Shyam Kottilil, et al.. (2017). Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clinical Infectious Diseases. 65(1). 6–12. 102 indexed citations

Mogalian, Erik, Polina German, Brian P. Kearney, et al.. (2017). Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 61(5). 32 indexed citations

10.

Stein, Stephen W., et al.. (2015). Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs. Molecular Pharmaceutics. 12(9). 3455–3467. 6 indexed citations

11.

Mogalian, Erik, Polina German, Brian P. Kearney, et al.. (2015). Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. Clinical Pharmacokinetics. 55(5). 605–613. 41 indexed citations

12.

Pianko, Stephen, Steven L. Flamm, Mitchell L. Shiffman, et al.. (2015). Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection. Annals of Internal Medicine. 163(11). 809–817. 66 indexed citations

13.

Lawitz, Eric, Daniel Gruener, Thomas Marbury, et al.. (2014). Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C. Antiviral Therapy. 20(7). 699–708. 27 indexed citations

14.

Karlage, Kelly L., et al.. (2010). Inhalation of an Ethanol-Based Zileuton Formulation Provides a Reduction of Pulmonary Adenomas in the A/J Mouse Model. AAPS PharmSciTech. 11(1). 168–173. 6 indexed citations

15.

Sanghvi, Ritesh, Erik Mogalian, Stephen G. Machatha, et al.. (2008). Preformulation and pharmacokinetic studies on antalarmin: A novel stress inhibitor. Journal of Pharmaceutical Sciences. 98(1). 205–214. 11 indexed citations

16.

Mogalian, Erik, Philip J. Kuehl, & Paul B. Myrdal. (2007). New analytical techniques to facilitate preformulation screening in propellant systems. International Journal of Pharmaceutics. 340(1-2). 223–229. 3 indexed citations

17.

Myrdal, Paul B., et al.. (2006). Application of Heated Inlet Extensions to the TSI 3306/3321 System: Comparison with the Andersen Cascade Impactor and Next Generation Impactor. Journal of Aerosol Medicine. 19(4). 543–554. 4 indexed citations

18.

Mogalian, Erik & Paul B. Myrdal. (2005). Application of USP Inlet Extensions to the TSI Impactor System 3306/3320 Using HFA 227 Based Solution Metered Dose Inhalers. Drug Development and Industrial Pharmacy. 31(10). 977–985. 8 indexed citations

19.

Mogalian, Erik, et al.. (2005). Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols. American Journal of Health-System Pharmacy. 62(21). 2271–2277. 16 indexed citations

20.

Myrdal, Paul B., et al.. (2004). Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: Solution Metered Dose Inhalers. Drug Development and Industrial Pharmacy. 30(8). 859–868. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact